A global multicenter phase III double-blind study known as ADAURA (100) has confirmed the considerable extension of DFS in patients with EGFR mutation-positive NSCLC (stages IB to IIIA) through the use of osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.